.png)
AstraZeneca Pharma India has received CDSCO approval to import and market Imfinzi for an additional cancer indication, expanding treatment options for advanced and recurrent endometrial cancer patients in India.
.png)
Roche’s experimental drug, fenebrutinib, has successfully passed its late-stage trial, offering hope for patients with multiple sclerosis. The drug significantly reduced disease relapses, marking a critical milestone in MS treatment.
Fujifilm India today launched four new diagnostic imaging and healthcare IT solutions at IRIA 2026, highlighting its focus on AI-enabled systems, workflow efficiency, and wider access to advanced imaging across India.
Sanofi has reported positive phase 3 data for venglustat in type 3 Gaucher disease, showing meaningful neurological improvements and comparable non-neurological outcomes versus enzyme replacement therapy.
Sun Pharma Advanced Research Company has secured an FDA Priority Review Voucher tied to its neonatal seizure drug Sezaby, strengthening its regulatory position and offering strategic flexibility for future drug approvals.
.png)
AstraZeneca Pharma India has received CDSCO approval for Durvalumab with FLOT chemotherapy, making it the first perioperative immunotherapy option for adults with resectable gastric and gastroesophageal junction cancer.
Alembic Pharmaceuticals has received final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%, used to treat post-surgery eye inflammation and anterior uveitis, further strengthening its US generics portfolio.
In a first-of-its-kind initiative, Gleneagles Hospital has introduced an AI-enabled Hub-and-Spoke stroke model that connects diagnostic centers across Mumbai and Navi Mumbai to its stroke team in real time, helping detect strokes early, reduce...
Natural Remedies shines at IPPE 2026, showcasing its science-backed phytogenics like NR-SBP. Their focus on sustainability, animal care, and productivity sets a new industry standard.
Roche has reported striking Phase II data for its CT-388 obesity drug, with patients achieving up to 22.5% weight loss over 48 weeks and strong metabolic improvements, supporting rapid advancement into Phase III trials.
.jpg)
, CDSCO.jpg)